Alexion’s Translational Medicine group comprises a cross-functional team of world-class scientists working to accelerate
the progression of highly innovative early-stage product candidates into clinical trials. The team’s talent and expertise
lie in discovery research, protein engineering, pharmacology, toxicology and clinical research. Translational research efforts
at the Cambridge, Mass.-based center of excellence focus on a broad range of novel preclinical and early stage clinical molecules,
including antibodies, small molecules and protein therapeutics, some of which are novel inhibitors of the complement system.
The Translational Medicine team is a critical driver of Alexion’s mission to create highly innovative treatments that
serve greater numbers of patients suffering from devastating diseases.